AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2018

Jan 31, 2018

SEC Form 4/A — Form 4/A

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2018-01-23

Reporting Person: CELGENE CORP /DE/ (10% Owner)
Reporting Person: Celgene Switzerland LLC (10% Owner)
Reporting Person: Celgene Alpine Investment Co., LLC (10% Owner)
Reporting Person: Celgene European Investment Co LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-01-23	Common Stock	P	851154	$67.00	Acquired	1374599	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5343834	Indirect

Footnotes

F1: This Form 4 Amendment is being submitted to correct the date of earliest transaction in box 3 to reflect January 23, 2018.

F2: Of these shares, 624,575 shares are owned directly by Celgene Switzerland LLC, 708,333 shares are owned directly by Celgene Alpine Investment Co. LLC, and 4,010,926 shares are owned directly by Celgene European Investment Company LLC, each a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all such shares. Celgene disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.